Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $18.90 up 12.17% from its previous closing price of $16.85. In other words, the price has increased by $12.17 from its previous closing price. On the day, 2.7 million shares were traded. DNLI stock price reached its highest trading level at $20.25 during the session, while it also had its lowest trading level at $17.0.
Ratios:
For a deeper understanding of Denali Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.79 and its Current Ratio is at 11.79. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when SATO VICKI L sold 1,666 shares for $18.29 per share. The transaction valued at 30,471 led to the insider holds 118,043 shares of the business.
Krognes Steve E. sold 92,500 shares of DNLI for $1,896,250 on Apr 01 ’24. The Director now owns 47,341 shares after completing the transaction at $20.50 per share. On Mar 15 ’24, another insider, SATO VICKI L, who serves as the Director of the company, sold 1,666 shares for $20.10 each. As a result, the insider received 33,487 and left with 119,709 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2694006016 and an Enterprise Value of 1631137536. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.12 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 5.522 whereas that against EBITDA is -7.874.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.34, which has changed by -0.40606272 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.31, while it has fallen to a 52-week low of $14.56. The 50-Day Moving Average of the stock is 0.11%, while the 200-Day Moving Average is calculated to be -6.68%.
Shares Statistics:
For the past three months, DNLI has traded an average of 1.26M shares per day and 998890 over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 128.66M. Insiders hold about 9.73% of the company’s shares, while institutions hold 76.29% stake in the company. Shares short for DNLI as of 1713139200 were 9575705 with a Short Ratio of 7.63, compared to 1710460800 on 8384423. Therefore, it implies a Short% of Shares Outstanding of 9575705 and a Short% of Float of 7.870000000000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 15.0 analysts currently analyzing and rating the stock of Denali Therapeutics Inc (DNLI).On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.44 and a low estimate of -$0.85, while EPS last year was $1.3. The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.39 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$1.12 and -$3.42 for the fiscal current year, implying an average EPS of -$2.6. EPS for the following year is -$2.59, with 14.0 analysts recommending between -$1.0 and -$3.8.
